Sunday 11 October 2026 Export all NVO data to Excel Powerpack

Novo Nordisk A/S

NVO Healthcare Drug Manufacturers General

Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024. In the quarter to June 2026, revenue grew 4.47%, EPS fell 18.7%, free cash flow grew 71.6% and total debt rose 44.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for five.

38.64 0.46 +1.20%
Market cap
$127.8B
P/E
9.4×
Fwd P/E
—
Dividend yield
4.65%
F-score
5/9
Altman Z
4.32
Beneish M
−2.51
Dividend safety
46/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

68.91% 61.81% 74.07% 60.84%
Piotroski F-Score
4 5 5 5
ROA
22.03% 20.71% 24.29% 22.00%
ROIC
33.99% 27.38% 28.59% 28.67%
Return on Tangible Assets
69.35% 62.02% 70.54% 58.25%
Average Days of Receivables
113.04 105.33 112.52 119.76
Free Cash Flow per Share
2.12 0.99 1.10 1.72
Free Cash Flow
9,416.60 4,388.93 4,863.47 7,610.53
Capital Expenditures
(9,564.48) (13,643.11) (13,470.33) (12,814.25)
Other line items
Cash ROIC
19.20% 8.08% 8.28% 11.92%
Accounts Receivable Turnover
3.57 3.58 3.65 3.44
Accounts Payable Turnover
2.31 2.48 3.63 3.02
Inventory Turnover
1.30 1.32 1.31 1.33
Average Days of Payables
161.91 122.67 91.86 83.55
Days of Inventory on Hand
321.75 308.10 318.66 294.06
Tax Rate
(0.21) (0.22) (0.22) (0.22)
Research and Development Expense of Revenue
16.33% 16.84% 15.77% 17.54%
Selling, General and Administrative Expense of Revenue
23.22% 22.74% 20.49% 19.64%
Share Based Compensation of Revenue
0.00% 1.96% 0.00% 0.00%
Interest Coverage
11.73 18.83 27.52 69.27
Operating CF/Net income
1.24 1.16 0.96 1.12
Depreciation/Fixed assets
0.11 0.11 0.10 0.12
Capex/Depreciation
(2.91) (4.10) (4.03) (3.08)
Revenue per Share
10.51 10.53 11.47 11.60
Operating CF per Share
4.27 4.06 4.13 4.60
Capex per Share
(2.15) (3.07) (3.03) (2.89)
Capex to Sales
0.20 0.29 0.26 0.25

Fold the line items

Columns are period end dates